Basic Information
ID: ALA4337961
Type: Binding
Description: Inhibition of N-[2-[(3',6'-dihydroxy-1-oxo-spiro[isobenzofuran-3,9'-xanthene]-5-yl)carbamothioylamino]ethyl]-N'-[6-[4-[5-[[2-(2-pyridyl)acetyl]amino]-1,3,4-thiadiazol-2-yl]butyl]pyridazin-3-yl]pentanediamide binding to human GLS1 expressed in Escherichia coli strain BL21 (DE3)pLysS at 10 uM by fluorescence polarization binding assay relative to control
Format: BAO_0000019
Organism: Homo sapiens
Target: Glutaminase kidney isoform, mitochondrial(ALA2146302)
Document: ALA4334507
Inhibition of N-[2-[(3',6'-dihydroxy-1-oxo-spiro[isobenzofuran-3,9'-xanthene]-5-yl)carbamothioylamino]ethyl]-N'-[6-[4-[5-[[2-(2-pyridyl)acetyl]amino]-1,3,4-thiadiazol-2-yl]butyl]pyridazin-3-yl]pentanediamide binding to human GLS1 expressed in Escherichia coli strain BL21 (DE3)pLysS at 10 uM by fluorescence polarization binding assay relative to control: 1
Activity Charts
Bioactivity
Activity Types for Assay ALA4337961
Inhibition
Compound Summary
| Parent Molecular Weight | ALogP | Polar Surface Area |
|---|---|---|
| 524.70 | 4.27 | 4.27 |
| 647.79 | 4.36 | 4.36 |
| 617.76 | 4.36 | 4.36 |
| 577.67 | 4.17 | 4.17 |
| 559.68 | 4.03 | 4.03 |
| 627.68 | 5.05 | 5.05 |
| 574.70 | 3.62 | 3.62 |
| 622.18 | 5.00 | 5.00 |
| 650.69 | 4.70 | 4.70 |
| 642.75 | 3.70 | 3.70 |
| 615.79 | 4.96 | 4.96 |
| 601.76 | 4.66 | 4.66 |
| 527.64 | 1.90 | 1.90 |
| 574.70 | 3.62 | 3.62 |
| 638.58 | 4.80 | 4.80 |
| 610.75 | 4.30 | 4.30 |
| 666.69 | 4.58 | 4.58 |
| 555.65 | 2.54 | 2.54 |
| 666.63 | 5.11 | 5.11 |
| 573.71 | 4.34 | 4.34 |
| 560.67 | 3.43 | 3.43 |
| 575.68 | 3.74 | 3.74 |
| 594.13 | 4.69 | 4.69 |
| 615.79 | 4.96 | 4.96 |
| 555.65 | 2.38 | 2.38 |
| 610.75 | 4.30 | 4.30 |
| 589.71 | 4.04 | 4.04 |
| 523.65 | 3.24 | 3.24 |
| 612.72 | 3.69 | 3.69 |
| 587.74 | 4.35 | 4.35 |
| 596.72 | 3.99 | 3.99 |
| 589.71 | 4.04 | 4.04 |
| 555.69 | 2.68 | 2.68 |
| 555.69 | 2.98 | 2.98 |
| 632.73 | 4.26 | 4.26 |
| 612.75 | 4.22 | 4.22 |
| 605.73 | 4.49 | 4.49 |